PKM2 in carcinogenesis and oncotherapy

Xia He; Suya Du; Tiantian Lei; Xiang Li; Yilong Liu; Hailian Wang; Rongsheng Tong; Yi Wang

doi:10.18632/oncotarget.22529

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

PKM2 in carcinogenesis and oncotherapy

Xia He, Suya Du, Tiantian Lei, Xiang Li, Yilong Liu, Hailian Wang, Rongsheng Tong and Yi Wang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:110656-110670. https://doi.org/10.18632/oncotarget.22529

Metrics: PDF 2502 views | HTML 4342 views | ?

Abstract

Xia He1,*, Suya Du2,*, Tiantian Lei2,*, Xiang Li2,*, Yilong Liu3, Hailian Wang4, Rongsheng Tong1 and Yi Wang1

1Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China

2School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China

3Department of Pharmacy, The People’s Hospital of Leshan, Leshan, Sichuan 614000, China

4Institute of Organ Transplantation, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China

*These authors have contributed equally to this work

Correspondence to:

Yi Wang, email: [email protected]

Rongsheng Tong, email: [email protected]

Keywords: PKM2; Warburg effect; aerobic glycolysis; carcinogenesis; oncotherapy

Received: August 16, 2017 Accepted: October 28, 2017 Published: November 20, 2017

ABSTRACT

Tumor cell metabolism is characterized by abundant glucose consumption and aerobic glycolysis. And pyruvate kinase M2 (PKM2) plays a decisive role in glycolysis, significantly contributing to the Warburg effect, tumor growth, angiogenesis, cell division, metastasis and apoptosis. To date, researchers have unraveled the potential of pyruvate kinase M2 as an antitumor target, which suggests a new orientation for oncotherapy. Herein, we focus on the role of pyruvate kinase M2 in tumor cell development and its function as a potential new therapeutic target for tumor treatment. Besides, research actuality on pyruvate kinase M2-dependent glycometabolism and signaling pathway in tumors is also summarized, providing valuable suggestions for further study in this field.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22529

Publication Alerts

Reviews:

PKM2 in carcinogenesis and oncotherapy

Abstract